Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Grows By 144.0%

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a significant growth in short interest in August. As of August 14th, there was short interest totaling 10,331,073 shares, a growth of 144.0% from the July 30th total of 4,234,144 shares. Based on an average daily volume of 60,973,817 shares, the short-interest ratio is presently 0.2 days. Approximately 1,266.1% of the shares of the company are sold short.

Analyst Ratings Changes

Several analysts have recently commented on LIMN shares. Weiss Ratings upgraded shares of Liminatus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Wall Street Zen downgraded shares of Liminatus Pharma to a “strong sell” rating in a research note on Saturday, August 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Liminatus Pharma currently has a consensus rating of “Sell”.

Liminatus Pharma Stock Performance

Shares of NASDAQ:LIMN traded down $0.17 during trading on Friday, hitting $4.23. The company’s stock had a trading volume of 38,621 shares, compared to its average volume of 655,043. The company has a market capitalization of $4.28 million, a PE ratio of -0.18 and a beta of 5.35. The stock’s 50-day moving average price is $5.70 and its two-hundred day moving average price is $9.53. Liminatus Pharma has a fifty-two week low of $4.23 and a fifty-two week high of $154.50.

Liminatus Pharma (NASDAQ:LIMN) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.50) earnings per share for the quarter.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.